Gülmezoglu A M, Hofmeyr G J
Special Department of Research, Development and Research Training in Human Reproduction, UNDP/UNFPA/WHO/World Bank, World Health Organisation, Geneva 27, Switzerland, CH-1211.
Cochrane Database Syst Rev. 2000;2003(2):CD000137. doi: 10.1002/14651858.CD000137.
Fetal hypoxaemia is often a feature of fetal growth impairment. It has been suggested that perinatal outcome after suspected impaired fetal growth might be improved by giving mothers continuous oxygen until delivery.
The objective was to assess the effects of maternal oxygen therapy in suspected impaired fetal growth on fetal growth and perinatal outcome.
We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register.
Acceptably controlled trials comparing maternal oxygen therapy with no oxygen therapy in suspected impaired fetal growth.
Eligibility and trial quality was assessed.
Two studies involving 62 women were included. Oxygenation compared with no oxygenation was associated with a lower perinatal mortality rate (relative risk 0.41, 95% confidence interval 0.21 to 0.78). However higher gestational age in the oxygenation groups may have accounted for the difference in mortality rates.
REVIEWER'S CONCLUSIONS: There is not enough evidence to evaluate the benefits and risks of maternal oxygen therapy for suspected impaired fetal growth.
胎儿低氧血症常为胎儿生长受限的一个特征。有人提出，对于疑似胎儿生长受限的孕妇，在分娩前持续给氧可能会改善围产期结局。
评估母体氧疗对疑似胎儿生长受限的胎儿生长及围产期结局的影响。
我们检索了Cochrane妊娠与分娩组试验注册库及Cochrane对照试验注册库。
在疑似胎儿生长受限的情况下，比较母体氧疗与不进行氧疗的可接受对照试验。
评估纳入标准及试验质量。
纳入两项研究，共62名女性。与未进行氧疗相比，进行氧疗的围产期死亡率较低（相对危险度0.41，95%置信区间0.21至0.78）。然而，氧疗组较高的孕周可能是死亡率差异的原因。
没有足够证据评估母体氧疗对疑似胎儿生长受限的益处和风险。
